A Multicenter, Open-Label, Phase II Study of Lapatinib in Combination With Vinorelbine in Subjects With ErbB2 Amplified Recurrent and Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2012
At a glance
- Drugs Lapatinib (Primary) ; Vinorelbine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 06 Apr 2012 Planned end date changed from 1 Dec 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
- 12 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 May 2010 New trial record